Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. While the exact cause of PJS is unknown, research has suggested that it is caused by a genetic mutation. This article will explore the link between genetics and PJS, discussing the genetic mutation that is believed to cause the disorder, and the implications of this mutation for diagnosis and treatment.
Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. The polyps are benign, meaning they are not cancerous, but they can cause problems with digestion and can lead to bleeding or blockages in the intestines. The dark spots are called “lentigines” and are caused by an increased number of melanocytes, the cells that produce pigment in the skin. PJS is usually diagnosed in childhood, but it can also be diagnosed in adulthood. The disorder is caused by a mutation in the STK11 gene, which is responsible for controlling cell growth. People with PJS have an increased risk of developing certain types of cancer, including colorectal, pancreatic, and gastric cancer.
The exact cause of PJS is unknown, but research has suggested that it is caused by a genetic mutation. The mutation occurs in the STK11 gene, which is responsible for controlling cell growth. People with PJS have an increased number of polyps in the gastrointestinal tract, as well as dark spots on the skin. The STK11 gene mutation is inherited in an autosomal dominant pattern, meaning that a person only needs one copy of the mutated gene to develop the disorder. People with PJS have a 50% chance of passing the mutated gene on to their children.
PJS can be difficult to diagnose, as the symptoms can be similar to other conditions. In order to diagnose PJS, doctors may perform genetic testing to look for the STK11 gene mutation. Additionally, doctors may perform an endoscopy or colonoscopy to look for the presence of polyps in the gastrointestinal tract. Once PJS is diagnosed, treatment typically involves monitoring the patient for any changes in the polyps or dark spots. Surgery may be recommended to remove any polyps that are causing problems. Additionally, people with PJS may be advised to undergo regular screening for certain types of cancer, as they are at an increased risk of developing these types of cancer.
Peutz-Jeghers Syndrome (PJS) is a rare genetic disorder that is caused by a mutation in the STK11 gene. This mutation is inherited in an autosomal dominant pattern, meaning that a person only needs one copy of the mutated gene to develop the disorder. PJS is characterized by the presence of polyps in the gastrointestinal tract and dark spots on the skin. Diagnosis of PJS involves genetic testing and endoscopy or colonoscopy, and treatment typically involves monitoring for changes in the polyps or dark spots, as well as regular screening for certain types of cancer.
1.
Recent Rise in Early-Onset Solid Tumors Is Associated with Accelerated Aging.
2.
Mammo Responsibility Increases Screening; Opioids for Pain Related to Cancer? Ignored CRC Signs.
3.
A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.
4.
Antitumor cell activity in glioblastoma is controlled by blocking the triggering receptor expressed on myeloid cells 2.
5.
Pancreatic cancer RNA vaccine shows durable T cell immunity
1.
Antibody-Drug Conjugates in Oncology: Breakthroughs, Clinical Updates, and Pipeline Innovation
2.
Understanding Hidrocystoma: Symptoms, Causes, and Treatment Options
3.
KEYNOTE-826: Optimizing Outcomes in Persistent, Recurrent, or Metastatic Cervical Cancer
4.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
5.
The Science Behind Thrombolytic Drugs and Their Benefits
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
2.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
Cost Burden/ Burden of Hospitalization For R/R ALL Patients
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation